Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Calliditas Therapeutics AB
AB
Active
Org 5566599766
Kungsbron 1, 111 22
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2004 · 22 years old
20-49 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Calliditas Therapeutics AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
2.4B
1.8B
1.2B
0.6B
0B
2020: 0.0B
0.0B
2020
2021: 0.2B (+22800% vs 2020)
0.2B
+22800%
2021
2022: 0.5B (+140% vs 2021)
0.5B
+140%
2022
2023: 0.8B (+47% vs 2022)
0.8B
+47%
2023
2025: 2.0B (+143% vs 2023)
2.0B
+143%
2025
EBITDA
SEK millions
0M
-111M
-222M
-332M
-443M
2020: -353M
-353M
2020
2021: -356M (-1% vs 2020)
-356M
-1%
2021
2022: -215M (+40% vs 2021)
-215M
+40%
2022
2023: -168M (+22% vs 2022)
-168M
+22%
2023
2025: -132M (+21% vs 2023)
-132M
+21%
2025
Income statement
SEK thousands
Item
2025
2023
2022
2021
2020
Revenue
1 958 890
805 551
548 977
229 347
874
Staff expenses
—
—
—
—
—
EBITDA
−132 292
−167 796
−215 364
−355 717
−352 567
Depreciation & amort.
—
—
—
—
—
EBIT
−132 292
−167 796
−215 364
−355 717
−352 567
Net financials
−942 048
−183 684
1 942
−833
−110 155
Profit before tax
−629 376
−273 518
−208 548
−354 405
−407 363
Tax
−0
−0
−0
−0
−0
Net profit
−629 376
−273 518
−208 548
−354 405
−407 363
Balance sheet
SEK thousands
Item
2025
2023
2022
2021
2020
Total assets
2 404 112
2 255 130
2 173 639
1 528 439
1 318 525
Equity
161 955
909 774
1 130 956
1 208 303
1 235 069
Long-term debt
1 534 915
981 918
717 485
189 269
105
Short-term debt
707 242
363 438
315 686
121 792
78 379
Total debt
2 242 157
1 345 356
1 033 171
311 061
78 484
Financial ratios
5-year trend
EBITDA margin
−6,8 %
This company
15,8 %
Market median
This company
Market median
143% below market
2020
2025
Equity ratio
6,7 %
This company
38,2 %
Market median
This company
Market median
82% below market
2020
2025
Return on equity
−388,6 %
This company
18,4 %
Market median
This company
Market median
>999% below market
2020
2025
Net profit margin
−32,1 %
This company
8,1 %
Market median
This company
Market median
496% below market
2020
2025
Asset turnover
0,81×
This company
1,12×
Market median
This company
Market median
28% below market
2020
2025
Debt / equity
13,84×
This company
0,62×
Market median
This company
Market median
>999% above market
2020
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2025-03-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Calliditas Therapeutics AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
